The abstract is read at the publisher; the summary is JClub's.
In five people with progressive or relapsing-remitting multiple sclerosis, autologous CD19 CAR T cells remodel the CSF B cell pool and sustain reduced CSF humoral biomarkers.
- Why it matters: Relapses can be controlled, but progression may persist due to incomplete access to or modulation of compartmentalized CNS inflammation.
- What they did: The study treated five individuals with progressive or relapsing-remitting MS using autologous CD19 CAR T cells, then profiled CSF and peripheral immune compartments for bioavailability and signature changes.
- The result: CSF-infiltrating CAR T cells selectively upregulate phosphodiesterase 7B, and peripheral B cells show altered cytokine and homing profiles, supporting compartment-specific immunomodulation and controlled trials.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.